Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
Rhea-AI Summary
Acurx Pharmaceuticals (NASDAQ: ACXP) will host a conference call on Friday, August 14, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and provide a business update.
The call will be led by President and CEO David P. Luci and CFO Robert G. Shawah.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | Earnings call scheduling | Negative | -0.8% | Announcement of Q1 2026 results conference call timing and access details. |
| Feb 16 | Earnings call scheduling | Positive | +0.5% | Scheduling of FY and Q4 2025 results call and related business update. |
| Oct 27 | Earnings call scheduling | Positive | +1.4% | Announcement of Q3 2025 results call date, time, and dial-in info. |
| Jul 24 | Earnings call scheduling | Negative | -1.1% | Scheduling notice for Q2 2025 financial results conference call. |
| Apr 30 | Earnings call scheduling | Positive | +2.4% | Notice of Q1 2025 results call and leadership-led business update. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past scheduling releases for earnings conference calls have typically led to modest single-day share moves, with no consistent directional trend around these announcements.
Historical Comparison
Over five prior earnings-call scheduling notices, same-tag headlines produced typical one-day moves of about 0.46%. This second-quarter call announcement fits that routine pattern of logistical updates rather than a new fundamental shift.
The company has repeatedly scheduled quarterly and year-end earnings calls with similar formats, reinforcing a steady cadence of financial reporting and business updates without indicating a distinct new phase in its development program.
Regulatory & Risk Context
Reported short interest is relatively low, suggesting limited squeeze potential and implying that trading volatility is more likely driven by financing and clinical catalysts than by heavy bearish positioning.
An effective $50 million S-3 shelf allows the company to issue various securities over three years, providing financing flexibility but also signaling ongoing dilution risk if capital is raised.
AI-generated analysis. How Rhea-AI works. Not financial advice.
David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:
Date: | Friday, August 14, 2026 |
Time: | 8:00 a.m. ET |
Toll free ( | 877-790-1503 Access ID: 13761686 |
Click here for participant International Toll-Free access numbers
About Ibezapolstat
Ibezapolstat is the Company's lead antibiotic candidate planning to advance to international Phase 3 clinical trials to treat patients with C. difficile infection. Ibezapolstat is a novel, orally administered antibiotic, being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome.
In June 2018, ibezapolstat was designated by the
Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. As previously announced, the Company has received final EMA and FDA agreement for our ibezapolstat pivotal Phase 3 trials in CDI. Their advice included and confirmed the non-inferiority study design elements, the patient population, primary and secondary endpoints, and size of the registration safety database. Acurx also now has a clear international roadmap for conduct of its Phase 3 program in CDI and, if successful, requirements for US NDA submission and EU Marketing Authorization.
Additionally, the Company has initiated start-up activities for a ground-breaking clinical trial in patients with multiply-recurrent CDI (rCDI) with the first patient expected to enroll in the fourth quarter this year. This trial begins with a 20-patient, open-label pilot trial in patients with multiply-recurrent CDI with at least 3 episodes of CDI and will inform elements of a planned active-controlled, Phase 3 registration trial in the rCDI. Upon subsequent successful completion of a Ph3 pivotal rCDI trial, and per the operative FDA procedure, Acurx plans to request FDA approval for treatment and prevention of rCDI under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (Guidance for Industry, 2020). Successful trial outcome has the potential to shift the paradigm of treatment and prevention of rCDI from two agents to one.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials next year. The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for post-exposure prophylaxis of inhalation anthrax is being planned in parallel.
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on for the quarter ended March 31, 2026, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-discuss-second-quarter-2026-financial-results-on-august-14-2026-conference-call-and-provide-business-update-302820298.html
SOURCE Acurx Pharmaceuticals, Inc.